Literature DB >> 7520089

Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.

W S Choi1, C Collignon, C Thiriart, D P Burns, E J Stott, K A Kent, R C Desrosiers.   

Abstract

The determinants of immune recognition by five monoclonal antibodies (KK5, KK9, KK17, Senv7.1, and Senv101.1) that neutralize simian immunodeficiency virus infectivity were analyzed. These five neutralizing monoclonal antibodies were generated to native SIVmac251 envelope glycoprotein expressed by a vaccinia virus recombinant vector. All five recognize conformational or discontinuous epitopes and require native antigen for optimal recognition. These monoclonal antibodies also recognize SIVmac239 gp120, but they do not recognize gp120 of two natural variants of SIVmac239, 1-12 and 8-22, which evolved during the course of persistent infection in vivo (D.P.W. Burns and R.C. Desrosiers, J. Virol. 65:1843-1854, 1991). Recombinant viruses which were constructed by exchanging variable regions between SIVmac239 and variant 1-12 were used to define domains important for recognition. Radioimmunoprecipitation analysis demonstrated that sequence changes in variable regions 4 and 5 (V4/V5) were primarily responsible for the loss of recognition of the 1-12 variant. Site-specific mutants were used to define precise changes that eliminate recognition by these neutralizing antibodies. Changing N-409 to D, deletion of KPKE, and deletion of KEQH in V4 each resulted in loss of recognition by all five monoclonal antibodies. SIVs with these natural sequence changes are still replication competent and viable. Changing A-417 to T or A/N-417/418 to TK in V4 or Q-477 to K in V5 did not alter recognition detectably. These results define specific, naturally occurring sequence changes in V4 of SIVmac that result in loss of recognition by one class of SIVmac neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520089      PMCID: PMC236939     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

2.  Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus.

Authors:  H Kestler; T Kodama; D Ringler; M Marthas; N Pedersen; A Lackner; D Regier; P Sehgal; M Daniel; N King
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

3.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.

Authors:  M Tremblay; M A Wainberg
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

5.  Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.

Authors:  K A Kent; L Gritz; G Stallard; M P Cranage; C Collignon; C Thiriart; T Corcoran; P Silvera; E J Stott
Journal:  AIDS       Date:  1991-07       Impact factor: 4.177

6.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.

Authors:  Y M Naidu; H W Kestler; Y Li; C V Butler; D P Silva; D K Schmidt; C D Troup; P K Sehgal; P Sonigo; M D Daniel
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.

Authors:  T Kodama; D P Burns; D P Silva; F D Veronese; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Neutralization-resistant antigenic variants of caprine arthritis-encephalitis lentivirus associated with progressive arthritis.

Authors:  W P Cheevers; D P Knowles; L K Norton
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

9.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

10.  Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis.

Authors:  T C McGuire; L K Norton; K I O'Rourke; W P Cheevers
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

View more
  24 in total

1.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Authors:  Melissa E Laird; Ronald C Desrosiers
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

4.  Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Authors:  Shuji Sato; Eloisa Yuste; William A Lauer; Eun Hyuk Chang; Jennifer S Morgan; Jacqueline G Bixby; Jeffrey D Lifson; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Authors:  Aravind Basavapathruni; Wendy W Yeh; Rory T Coffey; James B Whitney; Peter T Hraber; Ayush Giri; Bette T Korber; Srinivas S Rao; Gary J Nabel; John R Mascola; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

7.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

8.  Persistent infection of macaques with simian-human immunodeficiency viruses.

Authors:  J T Li; M Halloran; C I Lord; A Watson; J Ranchalis; M Fung; N L Letvin; J G Sodroski
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.

Authors:  Po-Jen Yen; Alon Herschhorn; Hillel Haim; Ignacio Salas; Christopher Gu; Joseph Sodroski; Dana Gabuzda
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.